|drug2955||SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant Wiki||1.00|
|drug2954||SCB-2019 with AS03 adjuvant Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
The anti-viral efficacy of ozone against RNA viruses is already established. Ozone gas have been already proposed as possible therapy for Covid-19 infection with insofar limited success. The development of ozonized oil (HOO) solved this problems making ozone highly stable and bioavailable due to its bound with the lipid carrier. HOO administration is totally noninvasive occurring by oral administration of pills or as nasal spray. HOO regimen could be proposed as complimentary therapeutic treatment for Covid-19 infection, without the need of any modifications of the established standard therapeutic protocols. This complimentary treatment, could be helpful to (a) decrease the severity of the diseases lowering the number of Covid-19 patients requiring high-intensity therapies; (b) fasten qPCR negativization after disease and time-span of hospital recovery. The objective of this study is to investigates the effectiveness of combined use of "HOO capsules" and "HOO oropharyngeal and nasal spray" as a therapeutic supplement in the treatment of patients with confirmed COVID-19, who are moderately ill.
Description: The study is aimed at defining if HOO therapy decreases the viral load of SARS-CoV-2 at day 7.Measure: Viral load of SARS-CoV-2 Time: up to one week
Description: The temporal profile of viral load at baseline, day 7, 14 and 28Measure: The temporal profile of viral load of SARS-CoV-2 Time: up to four weeks
Description: The proportion of patients with virological clearance at day 14 and 28Measure: The proportion of patients with virological clearance Time: up to four weeks
Description: Increasing SaO2, day 7, 14 and 28Measure: SaO2 Time: up to four weeks
Description: The hospitalization duration stayMeasure: hospitalization stay Time: through study completion, an average of 3 months
Description: Intensive care admission and time toMeasure: Intensive care Time: through study completion, an average of 3 months
Description: The COVID-19 Severity Score at day 14 and 28 Score definition: 1 is "no limitation of activities"; 2 is "limitation of activities"; 3 is "hospitalized, no oxygen therapy"; 4 is " hospitalized, oxygen by mask or nasal prongs"; 5 is "non-invasive ventilation or high-flow oxygen"; 6 is "intubation and mechanical ventilation"; 7 is "ventilation + additional organ support - pressors, RRT (renal replacement therapy), ECMO (extracorporeal membrane oxygenation)", and 8 is "death".Measure: COVID-19 Severity Score Time: up to four weeks
Description: Death occurred during hospitalization.Measure: in-hospital mortality Time: through study completion, an average of 3 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports